Dendritic cell CD83: A therapeutic target or innocent bystander?
- 15 January 2008
- journal article
- editorial
- Published by Elsevier BV in Immunology Letters
- Vol. 115 (1), 1-8
- https://doi.org/10.1016/j.imlet.2007.10.001
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: Implications for a lack of therapeutic potentialImmunology Letters, 2008
- A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allograftsTransplant International, 2006
- Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureusClinical and Experimental Allergy, 2006
- Determination of the inhibitory activity and biological half-live of soluble CD83: Comparison of wild type and mutant isoformsImmunobiology, 2006
- CD83 is a dimer: Comparative analysis of monomeric and dimeric isoformsBiochemical and Biophysical Research Communications, 2005
- Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83The Journal of Experimental Medicine, 2004
- Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83Blood, 2004
- Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell ArteritisThe Journal of Experimental Medicine, 2004
- Expression of CD83 in the murine immune systemMedical Microbiology and Immunology, 2003
- Hodgkin’s cells express CD83, a dendritic cell lineage associated antigenPathology, 1997